Adherence to the 2018 American College of Cardiology and American Heart Association Guideline on the Management of Blood Cholesterol in ambulatory care settings: A cross-sectional study

Background: Dyslipidaemia is a major risk factor for heart disease. Adherence to treatment guidelines can help manage dyslipidaemia and decrease the incidence of complications. Aim: To assess the adherence to the 2018 American College of Cardiology/American Heart Association Guideline on the Managem...

Full description

Saved in:
Bibliographic Details
Published inFarmacija Vol. 71; no. 1; pp. 1 - 7
Main Authors Tahaineh, Linda, Alsou'b, Nour
Format Journal Article
LanguageEnglish
Published Pensoft Publishers 17.06.2024
Subjects
Analysis
Anticholesteremic agents
Antilipemic agents
Blood cholesterol
Cardiology
Coronary heart disease
Fenofibrate
Health care industry
Low density lipoproteins
Medical research
Medicine, Experimental
Patient education
Prevention
Risk factors
Online AccessGet full text

Cover

More Information
Summary:Background: Dyslipidaemia is a major risk factor for heart disease. Adherence to treatment guidelines can help manage dyslipidaemia and decrease the incidence of complications. Aim: To assess the adherence to the 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol by healthcare providers who assessed ambulatory patients for dyslipidaemia in Jordan. Method: This was a multi-centre, prospective cross-sectional study. Adult patients assessed for dyslipidaemia were invited to participate in the study. Each patient's therapeutic plan was compared to the recommendations in the 2018 American College of Cardiology/American Heart Association Guideline, and adherence to the guideline was documented. Results: Three hundred patients were recruited. Twenty-eight patients (9.3%) were secondary prevention patients with a history of atherosclerotic cardiovascular disease. Of the 160 primary prevention patients, 83 (51.9%) were excluded from the analysis due to an inability to calculate the 10-year atherosclerotic cardiovascular disease risk, either due to missing information or the patient's age being under 40. One-quarter of secondary prevention patients were initiated on therapeutic plans according to the guideline. None of the primary prevention patients that required statin initiation according to the guideline were initiated on statins. Conclusion: Adherence to the 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol for ambulatory patients assessed for dyslipidaemia was suboptimal. Missing patient information that hinders the calculation of the 10-year atherosclerotic cardiovascular disease risk score needs to be addressed to facilitate compliance with the guideline. Keywords: dyslipidaemia, Jordan, primary prevention, secondary prevention
ISSN:0428-0296
2603-557X
DOI:10.3897/pharmacia.71.e125449